Latest news with #AaronDumas
Malaysian Reserve
3 days ago
- Business
- Malaysian Reserve
OGN Stockholders with Large Losses Should Contact Robbins LLP for Information About the Class Action Lawsuit Against Organon & Co.
SAN DIEGO, May 30, 2025 /PRNewswire/ — Robbins LLP reminds stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired Organon & Co. (NYSE: OGN) securities between October 31, 2024 and April 30, 2025. Organon is a global healthcare company with a primary focus on improving the health of women throughout their lives. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. The Allegations: Robbins LLP is Investigating Allegations that Organon & Co. (ORG) Misled Investors Regarding its Debt Reduction Strategy According to the complaint, during the class period, defendants provided investors with material information concerning Organon's prioritization of its capital allocation strategy through regular, quarterly dividends. Defendants' statements included, among other things, reassurance that capital allocation through the dividends was a '#1 capital allocation priority' and that Organon was committed to consistent deployment of capital. The complaint alleges that while defendants were making these positive statements, they were concealing the high priority of Organon's debt reduction strategy following the Company's acquisition of Dermavant, resulting in a 70% decrease for the regular quarterly dividend. The complaint further alleges that the truth came out on May 1, 2025, when Organon announced its first quarter 2025 results wherein management had reset the Company's dividend payout, from $0.28 to $0.02 to recapture capital for the Company. On this news, the price of Organon's common stock declined from $12.93 per share on April 30, 2025, to $9.45 per share on May 1, 2025, a decline of more than 27%. What Now: You may be eligible to participate in the class action against Organon & Co. Shareholders who want to serve as lead plaintiff for the class you should contact the firm. The lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, click here. All representation is on a contingency fee basis. Shareholders pay no fees or expenses. About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002. To be notified if a class action against Organon & Co. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today. Attorney Advertising. Past results do not guarantee a similar outcome.
Malaysian Reserve
3 days ago
- Business
- Malaysian Reserve
Robbins LLP Reminds Investors With Large Losses to Contact the Law Firm for Information About the Class Action Lawsuit Against DoubleVerify Holdings, Inc.
SAN DIEGO, May 30, 2025 /PRNewswire/ — Robbins LLP reminds stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired DoubleVerify Holdings, Inc. (NYSE: DV) common stock between November 10, 2023 and February 27, 2025. DoubleVerify operates a software platform for digital media measurement and advertising optimization services. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. The Allegations: Robbins LLP is Investigating Allegations that DoubleVerify Holdings, Inc. (DV) Misled Investors Regarding its Business Prospects According to the complaint, during the class period, defendants failed to disclose that: (a) DoubleVerify's customers were shifting their ad spending from open exchanges to closed platforms, where the Company's technological capabilities were limited and competed directly with native tools provided by platforms like Meta Platforms and Amazon; (b) DoubleVerify's ability to monetize on its Activation Services was limited because the development of its technology for closed platforms was significantly more expensive and time-consuming than disclosed to investors; (c) DoubleVerify's Activation Services in connection with certain closed platforms would take several years to monetize; (d) DoubleVerify's competitors were better positioned to incorporate AI into their offerings on closed platforms, which impaired DoubleVerify's ability to compete effectively and adversely impacted the Company's profits; (e) DoubleVerify systematically overbilled its customers for ad impressions served to declared bots operating out of known data center server farms; and (f) DoubleVerify's risk disclosures were materially false and misleading because they characterized adverse facts that had already materialized as mere possibilities. The complaint alleges that the truth was revealed on February 27, 2025, when DoubleVerify reported lower-than-expected fourth quarter 2024 sales and earnings due in part to reduced customer spending and the suspension of DoubleVerify services by a large customer. Defendants also disclosed that the shift of ad dollars from open exchanges to closed platforms was negatively impacting the Company. On this news, DoubleVerify's stock price dropped $7.83 per share, or 36%, from a closing price of $21.73 on February 27, 2025, to a closing price of $13.90 on February 28, 2025. What Now: You may be eligible to participate in the class action against DoubleVerify Holdings, Inc. Shareholders who want to serve as lead plaintiff for the class are required to file their papers with the court by July 15, 2025. The lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, click here. All representation is on a contingency fee basis. Shareholders pay no fees or expenses. About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002. To be notified if a class action against DoubleVerify Holdings, Inc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today. Attorney Advertising. Past results do not guarantee a similar outcome.
Malaysian Reserve
6 days ago
- Business
- Malaysian Reserve
ZBIO STOCKHOLDERS: Contact Robbins LLP for Information About How to Lead the Class Action Against Zenas BioPharma, Inc.
SAN DIEGO, May 27, 2025 /PRNewswire/ — Robbins LLP reminds stockholders that a class action was filed on behalf of all persons who purchased or otherwise acquired Zenas BioPharma, Inc. (NASDAQ: ZBIO) securities pursuant and/or traceable to the registration statement and related prospectus issued in connection with Zenas BioPharma's September 2024 initial public offering. Zenas BioPharma purports to be a 'clinical stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative immunology-based therapies for patients in need.' For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. The Allegations: Robbins LLP is Investigating Allegations that Zenas BioPharma, Inc. (ZBIO) Misled Investors in Connection with its IPO According to the complaint, defendants failed to disclose that in connection with its IPO, Zenas BioPharma materially overstated the amount of time that it would be able to fund its operations using existing cash and expected net proceeds from the IPO. On November 12, 2024, the Company filed with the SEC its quarterly report on Form 10-Q for the period ended September 30, 2024, stating that the Company could fund its operations for the following twelve months, not twenty-four, as it had stated in the Registration Statement. Since the IPO, and as a result of the disclosure of material adverse facts omitted from Zenas BioPharma's Registration Statement, Zenas BioPharma's share price has fallen substantially below its IPO price. As of the close of trading on April 15, 2025, the closing price of Zenas BioPharma stock was $8.72, 48.7% below the IPO price. What Now: You may be eligible to participate in the class action against Zenas BioPharma, Inc. Shareholders who want to serve as lead plaintiff for the class must file their papers with the court by June 16, 2025. The lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, click here. All representation is on a contingency fee basis. Shareholders pay no fees or expenses. About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002. To be notified if a class action against Zenas BioPharma, Inc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today. Attorney Advertising. Past results do not guarantee a similar outcome. Facebook:
Malaysian Reserve
6 days ago
- Business
- Malaysian Reserve
NPWR STOCKHOLDERS: Contact Robbins LLP for information About How to Lead the Class Action Against NET Power Inc.
SAN DIEGO, May 27, 2025 /PRNewswire/ — Robbins LLP reminds stockholders that a class action was filed on behalf of all persons and entities that purchased or otherwise acquired NET Power Inc. (NYSE: NPWR) securities between June 9, 2023 and March 7, 2025. NET Power is a clean energy technology company. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. The Allegations: Robbins LLP is Investigating Allegations that NET Power Inc. (NPWR) Misled Investors Regarding the Time and Capital Necessary to Complete Project Permian According to the complaint, during the class period, defendants failed to disclose that: (i) NET Power was unlikely to complete Project Permian on schedule, and the project was likely to be significantly more expensive than defendants had represented, because of, inter alia, supply chain issues and numerous site- and region-specific challenges; (ii) accordingly, defendants' projections regarding the time and capital needed to complete Project Permian were unrealistic; and (iii) the increased time and capital needed to complete Project Permian were likely to have a significant negative impact on the Company's business and financial results. Plaintiff alleges that on November 14, 2023, NET Power announced its third quarter 2023 results, disclosing that '[d]ue to . . . tightness in the global supply chain, we are incorporating a 12-month cushion into our expected schedule for Project Permian' with defendants 'now expecting to achieve initial power generation sometime between the second half of 2027 and first half of 2028.' On this news, NET Power's stock fell over 18%, to close at $10.85 per share on November 14, 2023. Plaintiff further alleges that on March 10, 2025, NET Power announce its fourth quarter and full year 2024 results, disclosing that it 'now estimates Project Permian's total installed cost to be between $1.7 billion and $2.0 billion'—significantly higher than its last estimate of $1.1 billion—'which is inclusive of non-recurring first-of-a-kind, Project Permian site-specific and owner costs[,]' advising that 'there are a number of site- and region-specific challenges which impact cost.' The Company further advised that Project Permian 'would come online no earlier than 2029[,]' representing a significant delay from its prior timeline of sometime between the second half of 2027 and first half of 2028. In addition, Net Power reported that it ended 2024 'with $533 million in cash, cash equivalents, and investments, down from $580 million last quarter, primarily due to $13 million in operating cash outflows and $29 million in capital expenditures for La Porte upgrades and SNI development.' On this news, NET Power's stock price fell over 31%, to close at $4.75 per share on March 10, 2025. What Now: You may be eligible to participate in the class action against NET Power Inc. Shareholders who want to serve as lead plaintiff for the class must file their papers with the court by June 17, 2025. The lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, click here. All representation is on a contingency fee basis. Shareholders pay no fees or expenses. About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002. To be notified if a class action against NET Power Inc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today. Attorney Advertising. Past results do not guarantee a similar outcome.
Associated Press
25-05-2025
- Business
- Associated Press
Organon & Co. Investor Notice: Robbins LLP Reminds Investors of the Class Action Against OGN
SAN DIEGO, May 25, 2025 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired Organon & Co. (NYSE: OGN) securities between October 31, 2024 and April 30, 2025. Organon is a global healthcare company with a primary focus on improving the health of women throughout their lives. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. The Allegations: Robbins LLP is Investigating Allegations that Organon & Co. (ORG) Misled Investors Regarding its Debt Reduction Strategy According to the complaint, during the class period, defendants provided investors with material information concerning Organon's prioritization of its capital allocation strategy through regular, quarterly dividends. Defendants' statements included, among other things, reassurance that capital allocation through the dividends was a '#1 capital allocation priority' and that Organon was committed to consistent deployment of capital. The complaint alleges that while defendants were making these positive statements, they were concealing the high priority of Organon's debt reduction strategy following the Company's acquisition of Dermavant, resulting in a 70% decrease for the regular quarterly dividend. The complaint further alleges that the truth came out on May 1, 2025, when Organon announced its first quarter 2025 results wherein management had reset the Company's dividend payout, from $0.28 to $0.02 to recapture capital for the Company. On this news, the price of Organon's common stock declined from $12.93 per share on April 30, 2025, to $9.45 per share on May 1, 2025, a decline of more than 27%. What Now: You may be eligible to participate in the class action against Organon & Co. Shareholders who want to serve as lead plaintiff for the class you should contact the firm. The lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, click here. All representation is on a contingency fee basis. Shareholders pay no fees or expenses. About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002. To be notified if a class action against Organon & Co. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today. Attorney Advertising. Past results do not guarantee a similar outcome. A photo accompanying this announcement is available at
